Company news
Bicara Therapeutics Inc. (NASDAQ:BCAX) news
Bicara Therapeutics Inc. news releases on 6ix. Latest, Oct 5, 2026: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 4, 2026
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
August 11, 2026
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
August 4, 2026
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
July 28, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 4, 2026
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 29, 2026
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 22, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 4, 2026
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 26, 2026
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
February 24, 2026
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 23, 2026
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
February 18, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 5, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 4, 2026
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
January 11, 2026
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
December 14, 2025
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
December 5, 2025
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
November 30, 2025
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 9, 2025
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
October 13, 2025
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
October 12, 2025
Bicara Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2025
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
June 11, 2025
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 2, 2025
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
May 31, 2025
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
May 21, 2025
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
April 27, 2025
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 22, 2025
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 26, 2025
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
March 24, 2025
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025